Moon Surgical Closes a $31.3 Million Series A Round led by GT Healthcare to Acce

Moon Surgical, a pioneer in collaborative robotics, today announced that it has secured $31.3 million in Series A funding. The financing round was led by GT Healthcare Capital & Partners, with participation by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Cathay Health, and existing investor, Sofinnova Partners.

More ›

【Portfolio News】Immunocore Holdings announces landmark FDA approval of TCR thera

GT portfolio company Immunocore Holdings plc (Nasdaq: IMCR) announces approval from the United States Food and Drug Administration (FDA) of KIMMTRAK® (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), the most common primary cancer within the eye in adults.

More ›

【Portfolio News】Portfolio ONI closes $75 Million Series B Led by ARCH Venture Pa

GT portfolio announces the closing of a $75M series B round led by ARCH Venture Partners and Casdin Capital, with participation from Section 32, ARTIS Ventures, Vertical Venture Partners, Axon Ventures and private investors, including Paul Conley. Existing investors, including Oxford Science Enterprises, and GT Healthcare Capital Partners also participated in the round.

More ›

Portfolio unicorns Oxford Nanopore Technologies and Exscientia g

We are proud to see two of our portfolio unicorn companies achieving significant milestones of successful initial public offerings. As innovative leaders in respective fields, Oxford Nanopore Technologies and Exscientia has revolutionized and led the technological and translational developments in nanopore sequencing and modernizing drug discovery & developments. We look forward to seeing these innovators taking stride in delivering innovation and improving patient care.

More ›

Exscientia announces multi-target, AI-driven drug discovery collaboration with B

Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY). This expanded collaboration has the potential to add to the Bristol Myers Squibb drug pipeline whilst enhancing Exscientia’s portfolio of shared assets. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology & immunology. The agreement includes up to $50 million in upfront funding, up to $125 million in near to mid-term potential milestones, and additional clinical, regulatory and commercial payments that take the potential value of the deal beyond $1.2 billion. Exscientia will also receive tiered royalties on net sales of any marketed drug products resulting from the collaboration.

More ›

Biotech unicorn Oxford Nanopore Technologies has raised £195 million in new capi

Oxford Nanopore Technologies, a next generation DNA/RNA sequencing technology company, recently has raise £195 million in new capital in a private transaction. £125 million of the investment comes from new investors Temasek, Wellington Management, M&G Investments and Nikon. In addition, existing shareholders invested £70 million.

More ›